Advertisement
U.S. markets close in 5 hours 36 minutes
  • S&P 500

    5,249.43
    +0.94 (+0.02%)
     
  • Dow 30

    39,753.49
    -6.59 (-0.02%)
     
  • Nasdaq

    16,381.10
    -18.42 (-0.11%)
     
  • Russell 2000

    2,121.45
    +7.10 (+0.34%)
     
  • Crude Oil

    82.32
    +0.97 (+1.19%)
     
  • Gold

    2,226.90
    +14.20 (+0.64%)
     
  • Silver

    24.70
    -0.05 (-0.21%)
     
  • EUR/USD

    1.0808
    -0.0021 (-0.19%)
     
  • 10-Yr Bond

    4.2020
    +0.0060 (+0.14%)
     
  • dólar/libra

    1.2637
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.2680
    +0.0220 (+0.01%)
     
  • Bitcoin USD

    70,953.03
    +1,363.44 (+1.96%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,963.32
    +31.34 (+0.40%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Eli Lilly's Ramucirumab for lung cancer meets Phase III survival endpoint

Eli Lilly announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer, showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel. REVEL also showed a statistically significant improvement in progression-free survival in the ramucirumab arm compared to the control arm. The most common adverse events occurring at a higher rate on the ramucirumab-plus-docetaxel arm were decreased white blood cell count (neutropenia/leukopenia), febrile neutropenia, fatigue/asthenia and hypertension. Lilly intends to submit the first application of these data to regulatory authorities in 2014.

Advertisement